Potentiating effects of nonactive/active vitamin D analogues and ketoconazole in parathyroid cells

Clinical Endocrinology

Volumn 66, Issue 3, 2007, Pages 399-404

  Segersten, Ulrika ^a   Björklund, Peyman ^a   Hellman, Per ^a   Åkerström, Göran ^a   Westin, Gunnar ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EB 1285; KETOCONAZOLE; MESSENGER RNA; OXYGENASE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ARTICLE; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; HORMONE INHIBITION; HUMAN; HUMAN CELL; PARATHYROID CELL; PARATHYROID FUNCTION; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY HYPERPARATHYROIDISM; TUMOR CELL;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ANIMALS; CATTLE; CELL PROLIFERATION; CELLS, CULTURED; DEPRESSION, CHEMICAL; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; KETOCONAZOLE; PARATHYROID GLANDS; PARATHYROID HORMONE; PARATHYROID NEOPLASMS; PRODRUGS; RECEPTORS, CALCITRIOL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEROID HYDROXYLASES; TUMOR CELLS, CULTURED; VITAMIN D;

EID: 33846922523     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2006.02746.x     Document Type: Article

References (36)

1. Beckerman, P. & Silver, J. (1999) Vitamin D and the parathyroid. American Journal of Medical Sciences, 317, 363-369.
2. Wu-Wong, J.R., Tian, J. & Goltzman, D. (2004) Vitamin D analogs as therapeutic agents: a clinical study update. Current Opinion in Investigational Drugs, 5, 320-326.
3. Akerstrom, G., Hellman, P., Hessman, O., Segersten, U. & Westin, G. (2005) Parathyroid glands in calcium regulation and human disease. Annals of the New York Academy of Sciences, 1040, 53-58.
4. Dusso, A.S., Brown, A.J. & Slatopolsky, E. (2005) Vitamin D. American Journal of Physiological and Renal Physiology, 289, F8-F28.
5. Segersten, U., Holm, P.K., Binderup, L., Akerstrom, G., Hellman, P. & Westin, G. (2004) Vitamin D3 polyunsaturated side-chain analogues (EB1089, GS1590) and the 20-epivitamin D3 analogue CB1393 suppress parathyroid hormone secretion and mRNA level in bovine parathyroid cells. Journal of Steroid Biochemistry and Molecular Biology, 88, 289-294.
6. Hewison, M., Zehnder, D., Bland, R. & Stewart, P.M. (2000) 1alpha-hydroxylase and the action of vitamin D. Journal of Molecular Endocrinology, 25, 141-148.
7. Prosser, D.E. & Jones, G. (2004) Enzymes involved in the activation and inactivation of vitamin D. Trends in Biochemical Sciences, 29, 664-673.
8. Segersten, U., Correa, P., Hewison, M., Hellman, P., Dralle, H., Carling, T., Akerstrom, G. & Westin, G. (2002) 25-hydroxyvitamin D(3)-1alpha hydroxylase expression in normal and pathological parathyroid glands. Journal of Clinical Endocrinology and Metabolism, 87, 2967-2972.
9. Correa, P., Segersten, U., Hellman, P., Akerstrom, G. & Westin, G. (2002) Increased 25-hydroxyvitamin D3, 1alpha-hydroxylase and reduced 25 hydroxyvitamin D3 24-hydroxylase expression in parathyroid tumors: new prospects for treatment of hyperparathyroidism with vitamin d. Journal of Clinical Endocrinology and Metabolism, 87, 5826-5829.
10. Correa Buchwald, P., Westin, G. & Akerstrom, G. (2005) Vitamin D in normal and pathological parathyroid glands: new prospects for treating hyperparathyroidism. International Journal of Molecular Medicine, 15, 701-706.
11. Peehl, D.M., Skowronski, R.J., Leung, G.K., Wong, S.T., Stamey, T.A. & Feldman, D. (1994) Antiproliferative effects of 1,25 dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Research, 54, 805-810.
12. Schwartz, G.G., Whitlatch, L.W., Chen, T.C., Lokeshwar, B.L. & Holick, M.F. (1998) Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25 hydroxyvitamin D3. Cancer Epidemiology Biomarkers & Prevention, 7, 391-395.
13. Tong, W.M., Bises, G., Sheinin, Y., Ellinger, A., Genser, D., Potzi, R., Wrba, F., Wenzl, E., Roka, R., Neuhold, N., Peterlik, M. & Cross, H.S. (1998) Establishment of primary cultures from human colonic tissue during tumor progression: vitamin D responses and vitamin-D-receptor expression. International Journal of Cancer, 75, 467-472.
14. Bareis, P., Bises, G., Bischof, M.G., Cross, H.S. & Peterlik, M. (2001) 25 hydroxyvitamin D metabolism in human colon cancer cells during tumor progression. Biochemical and Biophysical Research Communications, 285, 1012-1017.
15. Cross, H.S., Bareis, P., Hofer, H. et al. (2001) 25-hydroxyvitamin D(3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids, 66, 287-292.
16. Hsu, J.Y., Feldman, D., McNeal, J.E. & Peehl, D.M. (2001) Reduced 1alpha hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25 hydroxyvitamin D3-induced growth inhibition. Cancer Research, 61, 2852-2856.
17. Tangpricha, V., Flanagan, J.N., Whitlatch, L.W., Tseng, C.C., Chen, T.C., Holt, P.R., Lipkin, M.S. & Holick, M.F. (2001) Hydroxyvitamin D-1alpha hydroxylase in normal and malignant colon tissue. Lancet, 357, 1673-1674.
18. Ogunkolade, B.W., Boucher, B.J., Fairclough, P.D., Hitman, G.A., Dorudi, S., Jenkins, P.J. & Bustin, S.A. (2002) Expression of 25-hydroxyvitamin D-1-alpha hydroxylas mRNA in individuals with colorectal cancer. Lancet, 359, 1831-1832.
19. Kang, S., Li, X.Y., Duell, E.A. & Voorhees, J.J. (1997) The retinoid X receptor agonist 9 cis retinoic and the 24-hydroxylase inhibitor ketoconazole increase activity of 1,25-dihydroxyvitamin D3 in human skin in vivo. Journal of Investigative Dermatology, 108, 513-518.
20. Ly, L.H., Zhao, X.Y., Holloway, L. & Feldman, D. (1999) Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology, 140, 2071-2076.
21. Peehl, D.M., Seto, E., Hsu, J.Y. & Feldman, D. (2002) Clinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. Journal of Urology, 168, 1583-1588.
22. Schuster, I., Egger, H., Reddy, G.S. & Vorisek, G. (2003) Combination of vitamin D metabolites with selective inhibitors of vitamin D metabolism. Recent Results in Cancer Research, 164, 169-188.
23. Danilenko, M. & Studzinski, G.P. (2004) Enhancement by other compounds of the anti-cancer activity of vitamin D(3) and its analogs. Experimental Cell Research, 298, 339-358.
24. Rudberg, C., Grimelius, L., Johansson, H., Ljunghall, S., Odselius, R., Pertoft, H., Rastad, J., Wide, L. & Akerstrom, G. (1986) Alteration in density, morphology and parathyroid hormone release of dispersed parathyroid cells from patients with hyperparathyroidism. Acta Pathologica et Microbiologica Immunologica Scandinavica [A], 94, 253-261.
25. MacDonald, P.N., Ritter, C., Brown, A.J. & Slatopolsky, E. (1994) Retinoic acid suppresses parathyroid hormone (PTH) secretion and PreproPTH mRNA levels in bovine parathyroid cell culture. Journal of Clinical Investigations, 93, 725-730.
26. 2+ activity in parathyroid cells from patients with hyperparathyroidism. Bioscience Reports, 4, 909-915.
27. Wallfelt, C., Lindh, E., Larsson, R., Johansson, H., Rastad, J., Akerstrom, G. & Gylfe, E. (1988) Kinetic evidence for cytoplasmic calcium as an inhibitory messenger in parathyroid hormone release. Biochimica et Biophysica Acta, 969, 257-262.
28. Liu, W., Ridefelt, P., Akerstrom, G. & Hellman, P. (2001) Differentiation of human parathyroid cells in culture. Journal of Endocrinology, 168, 417-425.
29. 3 in cultured bovine parathyroid cells. Endocrinology, 130, 276-281.
30. Segersten, U., Holm, P.K., Bjorklund, P., Hessman, O., Nordgren, H., Binderup, L., Akerstrom, G., Hellman, P. & Westin, G. (2005) 25-hydroxyvitamin D3-1alpha hydroxylase expression in breast cancer and use of non-1alpha-hydroxylated vitamin D analogue. Breast Cancer Research, 7, R980-R986.
31. 3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. Journal of Clinical Investigations, 92, 1436-1443.
32. Sudhaker Rao, D., Han, Z.-H., Phillips, E.R., Palnitkar, S. & Parfitt, A.M. (2000) Reduced vitamin D receptor expression in parathyroid adenomas: implications for pathogenesis. Clinical Endocrinology, 53, 373-381.
33. Carling, T., Rastad, J., Szabo, E., Westin, G. & Akerstrom, G. (2000) Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 85, 2000-2003.
34. 3 and BCI-210 suppress PTH secretion by bovine parathyroid cells. Nephrology Dialysis Transplantation, 21, 644-650.
35. Kahraman, M., Sinishtaj, S., Dolan, P.M., Kensler, T.W., Peleg, S., Saha, U., Chuang, S.S., Bernstein, G., Korczak, B. & Posner, G.H. (2004) Potent, selective and low calcemic inhibitors of CYP24 hydroxylase: 24-sulfoximine analogues of the hormone 1alpha, 25-dihydroxyvitamin D(3). Journal of Medicinal Chemistry, 47, 6854-6863.
36. Fukagawa, M., Nakanishi, S. & Kazama, J.J. (2006) Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney International, 70, S3-S7.